AFP-464
Two Phase I studies with AFP-464 are currently enrolling in the United States, sponsored by the National Cancer Institute, at the Mayo Clinic, University of Maryland, and Wayne State University. These studies evaluate AFP-464 in patients with Advanced Solid Tumors. For more information on these trials, please use the link below:
ClinicalTrials.gov:
A Phase I study with AFP-464 is currently enrolling in Europe. This study evaluates AFP-464 in patients with Advanced Solid Tumors. The trials is expected to enroll up to 35 patients across two research centers in Europe, with Dr. Ahmad Awada at the Jules Bordet Institute, Brussels, Belgium and Dr. Jean Charles Soria at the Institut Gustave-Roussy Villejuif, France.
Following completion of these trials, Phase II studies of AFP-464 will commence.
GFB-204 and GGTI-2418
Tigris Pharmaceuticals is currently running preclinical IND enabling studies for GFB-204 and GGTI-2418 and is planning to initiate Phase I studies to evaluate GGTI-2418 as potential cancer therapeutics in patients with a variety of solid tumors upon IND acceptance.
|
